trending Market Intelligence /marketintelligence/en/news-insights/trending/rl9ffgxvzwdbhf_elmmyeq2 content esgSubNav
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it failed to comply with Nasdaq's $1 minimum bid price per common share.

The company has 180 calendar days, or until Feb. 25, 2019, to regain compliance.

The current notice has no immediate effect on the company's listing.

New Jersey-based ContraVir Pharmaceuticals develops antiviral drugs with a focus on hepatitis B.